Why the study?
Previous genetic engineering approaches to target cardiac fibrosis generated persistent cytolytic T cells that pose safety concerns in humans, motivating transient in vivo delivery.
Does targeted mRNA lipid nanoparticles delivering modified RNA to T cells in vivo improve cardiac function in a murine model of cardiac fibrosis?
Population
Murine model of cardiac fibrosis
Authors
Loading...
May inform cell therapy targets in cardiac fibrosis; leaves open human translation from this animal model.
Does targeted mRNA lipid nanoparticles delivering modified RNA to T cells in vivo improve cardiac function in a murine model of cardiac fibrosis?
In vivo delivery of modified RNA to T cells using targeted lipid nanoparticles creates a transient antiactivated fibroblast therapy that improves cardiac function in a murine model of cardiac fibrosis.
Rurik et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: